Loading…
Climb Bio, Inc. is projected to rise to $21.47 by 2027, a +53% move from its current price of $14.00. CLYM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $13.61 | $14.02 | $14.44 | +0.11% |
| Jul 15 | $13.45 | $14.03 | $14.63 | +0.22% |
| Jul 16 | $13.34 | $14.05 | $14.79 | +0.33% |
| Jul 17 | $13.25 | $14.06 | $14.92 | +0.44% |
| Jul 18 | $13.17 | $14.08 | $15.04 | +0.55% |
| Jul 19 | $13.10 | $14.09 | $15.16 | +0.66% |
| Jul 20 | $13.04 | $14.11 | $15.26 | +0.77% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $13.04 | $14.11 | $15.26 | +0.77% |
| Week 2 | $12.72 | $14.22 | $15.89 | +1.55% |
| Week 3 | $12.50 | $14.33 | $16.41 | +2.33% |
| Week 4 | $12.34 | $14.44 | $16.89 | +3.12% |
| Week 5 | $12.21 | $14.55 | $17.34 | +3.92% |
| Week 6 | $12.10 | $14.66 | $17.77 | +4.72% |
| Week 7 | $12.00 | $14.77 | $18.18 | +5.53% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company’s lead product candidate is budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell–mediated diseases.
Budoprutug is in Phase 2 clinical trials for primary membranous nephropathy and immune thrombocytopenia, and a Phase 1b program has indicated for systemic lupus erythematosus. In addition, Climb Bio is developing CLYM116, a preclinical anti-APRIL monoclonal antibody for the treatment of immunoglobulin A nephropathy and other B-cell–mediated diseases. The company was formerly known as Eliem Therapeutics, Inc.
and changed its name to Climb Bio, Inc. in October 2024. Climb Bio was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
Climb Bio Inc (CLYM) is a healthcare stock positioned in the biotechnology sector with a current price of $14.00 and a market cap of $801.68M. It ranks 2693 in market capitalization terms.
The stock shows a bullish near-term technical posture, with a 30-day price range of $11.51 to $17.03 and a current sentiment labeled as BULLISH. The 14-day RSI sits at 70, while the 50-day simple moving average is $11.50 and the 200-day moving average is $6.26. A near-term support level is at $10.44 and a resistance level at $14.00.
Looking longer term, the forecasted average price rises meaningfully through 2026–2050, with the 2026 average at $14.00 and the 2050 average at $192.84. The forecasted path features multiple upside milestones, including a 2040 average of $102.90 and a 2050 max of $367.98, underscored by continuing bullish sentiment.
A major floor 56.4% below — a decisive break under it would weaken the trend.
The nearest floor, 25.4% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 17.0% above — clearing it would confirm fresh momentum.
Key CLYM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CLYM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $13.62 | Buy | $13.66 | Buy |
| MA 10 | $13.37 | Buy | $13.32 | Buy |
| MA 20 | $12.55 | Buy | $12.73 | Buy |
| MA 50 | $11.50 | Buy | $11.45 | Buy |
| MA 100 | $9.45 | Buy | $9.71 | Buy |
| MA 200 | $6.26 | Buy | $7.47 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 68.87 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 112.85 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.08 | Buy |
| ROC (12) | 13.82 | Buy |
| Bollinger %B (20,2) | 0.87 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.81 | Buy |
| Awesome (5,34) | 1.67 | Buy |
| Ultimate (7,14,28) | 76.65 | Sell |
| Momentum (10) | 1.34 | Buy |
| Aroon Osc (25) | 100.00 | Buy |
| Hull MA (9) | 13.89 | Buy |
| ADX (14) | 24.44 | Buy |
| ATR (14) | 0.33 | Info |
The next 30 days show a bullish technical picture with RSI at 70, signaling stronger upside momentum. The stock’s near-term trend is supported by a SMA50 of $11.50 and a SMA200 of $6.26, suggesting the price could remain above key moving averages.
Support is identified at $10.44, with resistance at $14.00. The 30-day price range sits between $11.51 and $17.03, indicating potential volatility but with a bias toward further gains given the bullish technical setup.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.54 | $14.00 | $20.77 | 0% | Neutral | |
| $16.95 | $21.47 | $28.84 | +53% | Bullish | |
| $17.94 | $23.42 | $32.73 | +67% | Bullish | |
| $21.39 | $28.65 | $41.31 | +105% | Bullish | |
| $22.52 | $30.85 | $45.65 | +120% | Bullish | |
| $22.55 | $31.53 | $47.74 | +125% | Bullish | |
| $27.89 | $39.75 | $61.40 | +184% | Bullish | |
| $33.94 | $49.25 | $77.49 | +252% | Bullish | |
| $38.56 | $56.92 | $91.08 | +307% | Bullish | |
| $41.16 | $61.77 | $100.41 | +341% | Bullish | |
| $63.59 | $102.85 | $178.48 | +635% | Bullish | |
| $104.59 | $192.74 | $367.80 | +12.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.54 | $14.00 | $16.69 | +0.00% |
| August 2026 | $12.32 | $14.58 | $17.73 | +4.13% |
| September 2026 | $12.98 | $15.47 | $19.05 | +6.15% |
| October 2026 | $13.06 | $15.67 | $19.49 | +1.25% |
| November 2026 | $13.05 | $15.74 | $19.75 | +0.49% |
| December 2026 | $13.55 | $16.43 | $20.77 | +4.38% |
Click any year to see its month-by-month CLYM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The CLYM price prediction for 2026 points to an average of $14.00 (low $3.54, high $20.77) — a potential gain of 0% on today's $14.00. Price action looks broadly range-bound.
In 2027, CLYM is projected to trade between $16.95 and $28.84, averaging $21.47 — a potential gain of +53% from today's $14.00. That is up +53% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Climb Bio, Inc.'s 2028 outlook centres on $23.42, within a $17.94 to $32.73 range. That is up +9% on the projected 2027 average. That marks a +67% change versus current levels. Momentum favours further upside here.
By 2029, CLYM could reach as high as $41.31, with a base case around $28.65 and support toward $21.39 — roughly +105% from $14.00. Buyers look set to stay in control over this stretch.
Expect CLYM to range from $22.52 to $45.65 through 2030. The $30.85 average target implies a +120% move from current prices. That is up +8% on the projected 2029 average. Momentum favours further upside here.
The CLYM price prediction for 2031 points to an average of $31.53 (low $22.55, high $47.74) — a potential gain of +125% on today's $14.00. Buyers look set to stay in control over this stretch.
In 2032, CLYM is projected to trade between $27.89 and $61.40, averaging $39.75 — a potential gain of +184% from today's $14.00. That is up +26% on the projected 2031 average. Momentum favours further upside here.
Climb Bio, Inc.'s 2033 outlook centres on $49.25, within a $33.94 to $77.49 range. That is up +24% on the projected 2032 average. That marks a +252% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, CLYM could reach as high as $91.08, with a base case around $56.92 and support toward $38.56 — roughly +307% from $14.00. Momentum favours further upside here.
Expect CLYM to range from $41.16 to $100.41 through 2035. The $61.77 average target implies a +341% move from current prices. That is up +9% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The CLYM price prediction for 2040 points to an average of $102.85 (low $63.59, high $178.48) — a potential gain of +635% on today's $14.00. Momentum favours further upside here.
In 2050, CLYM is projected to trade between $104.59 and $367.80, averaging $192.74 — a potential gain of +12.8x from today's $14.00. That is up +87% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in CLYM today (≈ 71.428571 CLYM) could be worth
$13,767.36
+$12,767.36 (+1277%) by 2050 · US Dollar
Based on the average projected CLYM price of $192.74 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CLYMwould be worth at today's price.
$1,000 invested in CLYM on Jul 10, 2025 (≈ 740.740728 CLYM) would be worth
$10,370.37
+$9,370.37 (+937.0%) today · 10.37× · US Dollar
Based on a CLYM entry price of $1.35 vs. today's $14.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $12.9 | $1,085.27 | +8.5% |
| 1 month ago | $10.8 | $1,296.3 | +29.6% |
| 3 months ago | $8.41 | $1,664.68 | +66.5% |
| 6 months ago | $4.7 | $2,978.72 | +197.9% |
| 1 year ago | $1.35 | $10,370.37 | +937.0% |
| All time (4.9y) ago | $15.9 | $880.5 | -11.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CLYM forecast.
Our base-case forecast reaches $28.00 around 2029.
Implied market cap at $28.00: $1.6B
The multi-year forecast depicts a bullish trajectory across key milestones. By 2026, the average price is projected at $14.00 with a 0% ROI and neutral sentiment, followed by stronger upside in subsequent years: 2027 avg $21.46 (ROI 53.3%, bullish), 2028 avg $23.43 (ROI 67.3%, bullish), and 2029 avg $28.69 (ROI 104.9%, bullish).
The path continues higher, with 2030 avg $30.83 (ROI 120.2%, bullish) and 2031 avg $31.52 (ROI 125.2%, bullish). By 2032, the average is $39.82 (ROI 184.4%), and 2033–2035 show strong gains with 2033 avg $49.25 (ROI 251.8%), 2034 avg $56.91 (ROI 306.5%), and 2035 avg $61.83 (ROI 341.6%), all labeled bullish.
The forecast accelerates further into 2040 (avg $102.90, ROI 635%, bullish) and culminates in 2050 (avg $192.84, ROI 1277.4%, bullish). These figures illustrate a sustained growth trajectory, though they remain estimates and are not guaranteed. Investors should consider the inherent uncertainty and the possibility of downside risk alongside any potential upside.
Tap a question to reveal the answer.
2030 avg $30.83; min $22.50; max $45.62; ROI 120.2%; sentiment BULLISH.
Forecasts show bullish sentiment in multiple years (2027 onward) with rising average prices and positive ROI, but these are estimates, not guarantees. Notable points include 2026 avg $14.00 (ROI 0%), 2027 avg $21.46 (ROI 53.3%), 2030 avg $30.83 (ROI 120.2%). Consider the uncertainty surrounding any forecast.
Yes. The 2035 max is $100.51, with an average of $61.83 and a min of $41.20; ROI is 341.6% and sentiment is BULLISH.
2050 avg $192.84; min $104.64; max $367.98; ROI 1277.4%; sentiment BULLISH.
Current price $14.00; Market cap $801.68M; Rank 2693.
Climb Bio, Inc. Community Discussion
0Share your Climb Bio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.